Mallinckrodt Inc., of St. Louis, said the Phase III trial of MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, met the primary efficacy endpoint of change in pain from baseline over 48 hours compared to placebo in managing moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate.